ASX ANNOUNCEMENT **25 November 2026**

Results of Annual General Meeting

Melbourne, Australia; 25 November 2026: Cynata Therapeutics Limited (ASX: "**CYP", "Cynata",** or the **"Company"**), advises that its Annual General Meeting of Shareholders was held today at Becketts Lawyers, Level 34, 120 Collins Street, Melbourne, VIC 3000 at 12.00 noon AEDT.

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange.

Resolutions 1 to 13 were carried on a poll, with Resolution 3 (Approval of 10% Placement Facility), Resolution 7 (Reinsertion of Proportional Takeover Approval Provisions) and Resolution 11 (Buy-back of Acuity Shares) being carried by a sufficient majority as special resolutions.

Further information required by section 251AA(2) of the *Corporations Act 2001 (Cth)* is attached.

-ENDS-

Authorised for release by the Board of Directors

CONTACT: investors@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited's (ASX: CYP) core asset is currently the Cymerus™ platform, which offers a genuinely differentiated approach to manufacturing mesenchymal stromal cells at commercial scale from a single, consistent cell source. The Board is now focused on evaluating the future development pathways available for this technology, and the broader strategic options open to the Company. This includes seeking opportunities to realise value from the Cymerus™ technology and obtaining rights to new assets.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Pty Ltd.

Results of Meeting

Cynata Therapeutics Limited

Annual General Meeting

Wednesday, 25 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Adoption of Remuneration Report	P	49,613,145 94.79%	780,195 1.49%	219,458	1,948,827 3.72%	54,810,410 98.60%	780,195 1.40%	219,458	-
2 Election of Dr Kilian Kelly as a Director	P	51,205,948 94.94%	760,880 1.41%	43,300	1,965,483 3.64%	56,419,869 98.67%	760,880 1.33%	43,300	Carried
3 Approval of 10% Placement Facility	P	51,201,157 94.98%	740,560 1.37%	68,411	1,965,483 3.65%	53,166,640 93.02%	3,988,998 6.98%	68,411	Carried
4 Ratification of the issue of Shares under the Placement	P	25,659,459 90.62%	691,788 2.44%	68,411	1,964,575 6.94%	27,624,034 97.56%	691,788 2.44%	68,411	Carried
5 Ratification of the issue of the Adviser Shares	P	48,936,837 94.85%	691,788 1.34%	110,411	1,964,575 3.81%	50,901,412 92.82%	3,940,226 7.18%	110,411	Carried
6 Approval of Issue of Equity Securities under Cynata Equity Incentive Plan	P	47,525,786 94.63%	729,945 1.45%	1,131,542	1,965,483 3.91%	49,491,269 92.56%	3,978,383 7.44%	1,131,542	Carried
7 Reinsertion of Proportional Takeover Approval Provisions	P	51,275,447 95.07%	691,681 1.28%	43,000	1,965,483 3.64%	56,489,368 98.79%	691,681 1.21%	43,000	Carried
8 Issue of Director Fee Rights to Dr Geoff Brooke in lieu of cash fees	P	49,819,408 94.86%	733,541 1.40%	1,107,232	1,964,575 3.74%	55,032,421 98.68%	733,541 1.32%	1,107,232	Carried
9 Issue of Director Fee Rights to Ms Janine Rolfe in lieu of cash fees	P	49,819,408 94.86%	733,541 1.40%	1,107,232	1,964,575 3.74%	55,032,421 98.68%	733,541 1.32%	1,107,232	Carried

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
10 Issue of Director Fee Rights to Dr Kilian Kelly in lieu of cash fees	P	49,819,408 94.86%	733,541 1.40%	1,107,232	1,964,575 3.74%	55,032,421 98.68%	733,541 1.32%	1,107,232	Carried
11 Buy-back of Acuity Shares	P	51,164,348 94.91%	736,476 1.37%	68,212	2,006,575 3.72%	56,419,361 98.71%	736,476 1.29%	68,212	Carried
12 Ratification of the issue of the Underwriter Options	P	15,626,896 85.26%	737,233 4.02%	35,646,907	1,964,575 10.72%	17,591,471 81.53%	3,985,671 18.47%	35,646,907	Carried
13 Election of Geoff Pocock as a Director	P	49,048,012 90.98%	801,952 1.49%	62,801	4,062,846 7.54%	53,110,858 92.91%	4,050,390 7.09%	62,801	Carried